Neurotoxicity risk assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a synthetic impurity of drugs
- 1 May 1998
- journal article
- research article
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 17 (5) , 283-293
- https://doi.org/10.1177/096032719801700514
Abstract
1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) induces symptoms indistinguishable from those of Parkinson's disease. It selectively destroys dopaminergic neurons in the substantia nigra and the globus pallidus. Death of these same neurons is apparently the cause of idiopathic Parkinson's disease. As phenyl-1,2,3,6 tetrahydropyridine is a commonly encountered subunit in heterocyclic drugs and because MPTP was found as a minor impurity in early batches of a candidate drug at Merck KGaA, it may be assumed that MPTP will also be present as an as yet undiscovered minor impurity in various existing drugs. A neurotoxicity risk assessment on MPTP has been conducted to define the risk of MPTP as an impurity in drugs that are used orally. This risk assessment has shown that compounds containing less than 5.0 p.p.m. MPTP administered orally will not cause a neurotoxicological health risk to patients treated with such a drug.Keywords
This publication has 16 references indexed in Scilit:
- Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboonsNeuroscience, 1993
- Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosetsEuropean Journal of Pharmacology, 1993
- Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmosetBrain Research, 1991
- Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?Neuroscience Letters, 1991
- Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to miceToxicology Letters, 1990
- Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeysBrain Research, 1990
- The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkeyBrain Research, 1990
- Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to miceLife Sciences, 1988
- 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's diseaseJournal of the Neurological Sciences, 1988
- Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP): Differential effects on depletion of heart norepinephrine and of striatal dopamine in miceBiochemical Pharmacology, 1987